A specialized liquid biopsy test designed to detect EGFR exon 14 skipping mutations in non-small cell lung cancer patients.
Manufactured by
Daejeon, South Korea
PANAGENE will always make its best efforts to develop innovative platform technologies and strive to be a global leader in the field of molecular diagnostics. We, PANAGENE Inc. have been developing and launching accurate and convenient in vitro diagnostic products consistently from Oncology to Infectious Diseases. We exercise strict quality management policy and make efforts to meet global standards and appropriate regulations for our IVD products. PANAGENE has expertise especially in cancer-related molecular diagnostics including companion diagnostics using tissue or liquid biopsy. Our advanced technology provides not only high level of detection but also simple and convenient procedure to be used easily in the front-line hospitals and clinical laboratories. (EGFR, KRAS, NRAS, BRAF, PIK3CA, IDH1, IDH2, JAK2, BCR-ABL, c-KIT, TERT, EML4-ALK, ROS1) Also we apply our platform technology to maximize multiplex capability to detect using melting curve analysis with high-level performance. (HPV, STD, CRE, TB/NTM) Lastly, we have our automation extraction system to use with molecular diagnostics kits to provide full package solution for the user. The extraction machine is 100% in house developed and optimized with our kits. During this Pandemic, we are providing the machines and extraction kits to reach out who needs the testings. (Viral, FFPE, cfDNA extraction kits) PANAGENE is pursuing open innovation and seeking opportunity for collaboration with various organizations including pharmaceutical and diagnostics companies. We always welcome organizations who are interest in our technologies and/or products. We will do our best for customer satisfaction and for realizing our vision, “Platform Technology Provider”.
✦ Product-Specific Coverage
Based on AI-matched alternatives related to this product across Suplivia's medical sourcing network.
Generated for this product
AI-matched supplier coverage based on related product alternatives.
GMA Group Trading
Egypt · 1 relevant product
BIOTYPE GmbH
Germany · 4 relevant products
Singlera GENOMICS (SHANGHAI) Ltd.
China · 4 relevant products
BioChain (Beijing) Science & Technology. Inc.
China · 3 relevant products
guangzhou biotron technolongy co.,ltd
China · 3 relevant products
Glycanostics, s.r.o.
Slovakia · 1 relevant product
Ease Healthcare
United States · 2 relevant products
Shanghai Biotecan pharmaceuticals Co.,Ltd
China · 2 relevant products
Wuhan YZY Medical Science and Technology Co.,Ltd.
China · 2 relevant products
GeneCker Co., Ltd.
South Korea · 3 relevant products
35 more relevant manufacturers available
Get free access to all relevant manufacturers for this product.
See all manufacturers →5 more sourcing countries available
Get free access to all sourcing countries identified for this product.
See all countries →See the full supplier coverage for this product
Get free access to all relevant manufacturers, sourcing countries, and product alternatives.
✓ Free for medical industry professionals.
from other manufacturers
from other manufacturers
12 of 99 closest product alternatives
GMA Group Trading · Egypt
Molecular test for detection of epidermal growth factor receptor mutations in lung cancer diagnosis.
BIOTYPE GmbH · Germany
A molecular diagnostic test for detecting EGFR mutations in tumor diagnostics and liquid biopsy applications. Version 2 provides improved performance for cancer biomarker detection.
Singlera GENOMICS (SHANGHAI) Ltd. · China
A liquid biopsy-based test utilizing DNA methylation markers for post-treatment cancer recurrence monitoring and surveillance. Enables early detection of disease relapse and progression.
Singlera GENOMICS (SHANGHAI) Ltd. · China
A molecular diagnostic test utilizing DNA methylation technology for early detection of lung cancer. Enables risk assessment and early diagnosis of lung malignancies through liquid biopsy methodology.
BioChain (Beijing) Science & Technology. Inc. · China
Advanced early detection test for lung cancer screening utilizing molecular diagnostic technology. This in-development product represents the company's expansion into early detection for pulmonary malignancies. The test is designed for high-risk population screening and clinical intervention.
guangzhou biotron technolongy co.,ltd · China
Liquid biopsy assay for real-time monitoring of circulating tumor markers and cells during perioperative periods to assess surgical outcomes and recurrence risk.
Glycanostics, s.r.o. · Slovakia
Non-invasive liquid biopsy test for early-stage prostate cancer detection using glycan analysis in blood serum. Achieves up to 90% accuracy using magnetic particle-based technology with minimal blood sample requirement of 10 microliters.
BIOTYPE GmbH · Germany
A molecular diagnostic test for detecting ESR1 mutations in tumor diagnostics. Used for biomarker analysis in cancer precision medicine.
Ease Healthcare · United States
LEAP is a simple blood test that helps doctors assess lung cancer risk in people who may be more vulnerable due to factors like age or smoking history, even if they have no symptoms.
Shanghai Biotecan pharmaceuticals Co.,Ltd · China
High-throughput sequencing detection service for tumor-derived circulating free DNA genetic mutations, enabling precise tumor profiling and monitoring. The service has passed national inter-laboratory quality assessments with full marks.
Singlera GENOMICS (SHANGHAI) Ltd. · China
A DNA methylation-based diagnostic solution for early detection of esophageal cancer. Enables risk assessment and molecular diagnosis of esophageal malignancies.
Wuhan YZY Medical Science and Technology Co.,Ltd. · China
In vitro diagnostic test for identifying genetic biomarkers that predict treatment response in cancer patients. Guides selection of targeted therapies and treatment protocols.
87 more product alternatives available
Create a free account to compare more product alternatives and supplier options.
© 2026 Suplivia · Home · Browse Products